Introduction {#section1-1534735415622011}
============

Primary liver cancer, mainly hepatocellular carcinoma (HCC), is the third leading cause of cancer deaths worldwide. The poor prognosis is attributed mainly to its high recurrence and metastasis rate,^[@bibr1-1534735415622011]^ and the lungs are the most common metastatic site.^[@bibr2-1534735415622011]^ Currently, the main strategies against HCC include surgery, regional therapy (transarterial chemoembolization, radiofrequency ablation, ethanol injection, etc), radiotherapy, and targeted therapy.^[@bibr3-1534735415622011],[@bibr4-1534735415622011]^ However, the effects of these measures are limited in the treatment of HCC. It is, thus, necessary to explore complementary approaches to preventing and limiting the progression of HCC. Immunity plays an emerging important role in the initiation and progression of cancer.^[@bibr5-1534735415622011]^ It is expected that immunotherapy will bring breakthroughs for future cancer treatment.^[@bibr6-1534735415622011]^ Physical exercise has been recognized to reduce the incidence and recurrence of cancers and improve survival by enhancing immunocompetence.^[@bibr7-1534735415622011][@bibr8-1534735415622011][@bibr9-1534735415622011]-[@bibr10-1534735415622011]^ In animal models, it has been found that swimming training could inhibit the growth of hepatoma in rat and mouse models by improving metabolism and immunity.^[@bibr11-1534735415622011][@bibr12-1534735415622011]-[@bibr13-1534735415622011]^ Chinese herbal traditional medicine shows effectiveness in the treatment of cancer.^[@bibr14-1534735415622011][@bibr15-1534735415622011]-[@bibr16-1534735415622011]^ *Songyou Yin* (SYY), a composite formula composed of 5 agents, has been demonstrated to suppress the growth, metastasis, and recurrence of HCC as well as prolong survival in the mouse model system.^[@bibr17-1534735415622011][@bibr18-1534735415622011][@bibr19-1534735415622011][@bibr20-1534735415622011]-[@bibr21-1534735415622011]^ Two components of SYY, *Astragalus membranaceus* and *Lycium barbarum* have been confirmed to have anticancer and immunomodulatory effects,^[@bibr22-1534735415622011],[@bibr23-1534735415622011]^ but the impact of SYY on immune function has not been clarified. A previous study showed that SYY could inhibit the expression of transforming growth factor (TGF)-β1 by activated hepatic stellate cells.^[@bibr21-1534735415622011]^ TGF-β1 is a potent inhibitor of immune function, which plays a key role in the proliferation and activation of regulatory T cells (Treg cells), a subgroup of T cells with immunosuppressive properties.^[@bibr22-1534735415622011]^ A previous study showed that both swimming exercise and SYY may have potential effects on immune modulation and tumor suppression. We investigated whether the 2 strategies have an enhanced effect against liver cancer. C57BL/6 immunocompetent mice transplanted with liver cancer cell lines were treated with SYY alone and combined with swimming training. We found that SYY combined with moderate swimming (MS) markedly suppressed growth and lung metastasis of transplanted liver cancer by raising the CD4 to CD8 ratio in the peripheral blood and reducing serum TGF-β1 levels and proportions of CD4 + CD25 + Foxp3 + Treg cells in peripheral blood, spleen, and tumor tissue in tumor-bearing mice; furthermore, SYY plus MS had an enhanced effect in suppressing tumor growth and metastasis and enhancing immunity. The effects were superior to SYY or MS alone.

Materials and Methods {#section2-1534735415622011}
=====================

Cell Line and Culture {#section3-1534735415622011}
---------------------

The murine liver cancer cell line Hepa1-6 was purchased from the cell bank of the Chinese Academy of Sciences (Shanghai, China) and was maintained in Dulbecco's modified eagle medium (Genom, Hangzhou, China), supplemented with 10% fetal bovine serum (Gibco, Carlsbad, CA) and 1% penicillin-streptomycin (Genom, Hangzhou, China). For in vivo injections, cancer cells were trypsinized and centrifuged at 1000 rpm for 5 minutes at 4°C, washed twice, and reconstituted in phosphate buffered saline solution (PBS) (Genom, Hangzhou, China).

Animals and Hepatoma Model {#section4-1534735415622011}
--------------------------

A total of 48 male C57BL/6 mice (6 weeks old) were purchased from the Animal Center of the Chinese Academy of Science. The mice were habituated to vivarium conditions for 1 week before initiation of the intervention procedures. C57BL/6 mice were injected with Hepa1-6 cells subcutaneously (Hepa1-6, 5 × 10^6^ cells) and through the tail vein (Hepa1-6--green fluorescent protein \[GFP\], 3 × 10^6^ cells) to establish subcutaneous tumor and experimental lung metastasis models, respectively.^[@bibr23-1534735415622011]^ All experiments were approved by the Institutional Animal Care and Use Committee, Fudan University.

Characterization and Preparation of Herbal Extracts {#section5-1534735415622011}
---------------------------------------------------

The Chinese herbal medicine formula SYY, a dietary component, is authorized by the Chinese State Food and Drug Administration (Grant No. G20070160). The mixture includes 5 Chinese medicinal herbal extracts with a fingerprint in the following proportions (w/w): *Salvia miltiorrhiza* Bge, 14.3%; *A membranaceus* Bge, 14.3%; *L barbarum* L, 23.8%; *Crataegus pinnatifida* Bge, 23.8%, and *Trionyx sinensis* Wiegmann, 23.8% (all from China). The fingerprint and protocol of preparation have previously been reported.^[@bibr17-1534735415622011]^ SYY used in vitro with the same batch number (\#20120901) was produced by Shanghai Fang Xin Pharmaceutical Technology Co, Ltd. (Shanghai, China).

Mice Grouping and Treatment Schema {#section6-1534735415622011}
----------------------------------

The mice were divided into 4 groups (12 mice in each group): (1) control group, (2) SYY group, (3) MS group, and (4) SYY-MS group. Each mouse in the SYY group received 0.2 mL of SYY (4 g/kg/d per mouse) via the oral gavage method after inoculation. The MS group mice were subjected to swimming training in water (28°C-30°C) 5 days per week. For adaptation to swimming, all trained mice swam 5 minutes in the first week, 6 min/d in the second week, and 8 min/d in the third week. The mice were injected with liver cancer lines at the end of the third week. This level of swimming (8 min/d) was maintained after inoculation. Based on our pilot study, voluntary swimming for 8 min/d was defined as *moderate swimming*. The SYY-SM group combined application of SYY and MS. At day 42 after inoculation, 6 mice of each group were killed humanely by cervical dislocation under anesthesia, and peripheral blood, subcutaneous tumor, spleen, and lung were retrieved for examination; the remaining mice of each group were maintained for survival observation. Subcutaneous tumors were completely stripped from mice and then weighed using a precision electronic scale.

Lung Metastasis Evaluation {#section7-1534735415622011}
--------------------------

The fluorescent protein--positive (GFP) metastatic foci in lungs were imaged with a stereoscopic fluorescence microscope (Leica M205FA, Image Source: Leica DFC500, Germany); then, Image-Pro Plus software (Media Cybernetics, Bethesda, MD) was used to calculate the ratio of total size of metastatic foci to the size of a whole lung. This ratio was called the lung metastases ratio.

Flow Cytometry for CD4+, CD8+ T lymphocyte, CD4+ CD25+ Foxp3+ Treg Cell Detection {#section8-1534735415622011}
---------------------------------------------------------------------------------

The peripheral blood, spleen, and tumor tissue were acquired from mice under anesthesia using aseptic procedures. The procedures of isolation of peripheral blood monocyte (PBMC), spleen lymphocyte, and tumor-infiltrating lymphocyte (TIL) conform to those in the previous report.^[@bibr24-1534735415622011],[@bibr25-1534735415622011]^ Isolated lymphocytes were washed with PBS supplemented with 2% fetal bovine serum. The washed cells were incubated with antimouse CD3-FITC, CD4-PC, and CD8-PE (BD Pharmingen, USA) at 4°C for 15 minutes. Tregs were detected using a mouse Treg detection kit (anti-CD4-FITC/anti-CD25-APC/anti-FoxP3-PE) in accordance with the manufacturer's instructions (Miltenyi Biotec, Germany). Then, fluorescent antibody incubated cells were analyzed with flow cytometry using a FACSCalibur (BD Pharmingen, USA).

Determination of TGF-β1 Concentration in the Serum of Mice {#section9-1534735415622011}
----------------------------------------------------------

TGF-β1 levels were detected in the serum of mice using a mouse TGF-β1 ELISA kit (Boster, Wuhan, China) in accordance with the manufacturer's instructions.

Statistical Analysis {#section10-1534735415622011}
--------------------

All statistical analyses were performed using SPSS v17. Continuous variables were compared with the Student's *t* test (between 2 groups) or analysis of variance (ANOVA, among all groups) if normally distributed. Kaplan-Meier survival analysis with the log-rank test was used to evaluate the relationship between various interventions and survival. For the analysis, a *P* value \<.05 in a 2-tailed test was considered statistically significant. Charts and graphs were drawn with GraphPad Prism 5.0.

Results {#section11-1534735415622011}
=======

SYY Combined With MS Significantly Suppressed Growth and Lung Metastasis of Transplanted Liver Cancer and Prolonged Survival in a Mouse Model {#section12-1534735415622011}
---------------------------------------------------------------------------------------------------------------------------------------------

On day 42 after inoculation of liver cancer cell lines, compared with the control group, the mean weight of the subcutaneous tumors was reduced by 22.9% in the SYY group (control 3.19 ± 1.12 g vs SYY 2.46 ± 0.77 g, *P* \< .05), 19.4% in the MS group (control 3.19 ± 1.12 g vs MS 2.57 ± 0.68 g, *P* \< .05), and 56.4% in the SYY-MS groups (control 3.19 ± 1.12 g vs SYY-MS 1.39 ± 0.52 g, *P* \< .01; [Figures 1A](#fig1-1534735415622011){ref-type="fig"} and [1B](#fig1-1534735415622011){ref-type="fig"}). Compared with the control group, the mean lung metastases ratio was reduced by 35.6% in the SYY group (control 10.16% ± 4.13% vs SYY 6.54% ± 3.21%, *P* \< .05), 34.3% in the MS group (control 10.16% ± 4.13% vs MS 6.68% ± 2.79%, *P* \< .05), and 54.5% in the SYY-MS groups (control 10.16% ± 4.13% vs SYY-MS 4.62% ± 1.83%, *P* \< .01; [Figures 1C](#fig1-1534735415622011){ref-type="fig"} and [1D](#fig1-1534735415622011){ref-type="fig"}). In the log-rank survival analysis, the median survival time, compared with the control group, was prolonged by 8 days in the SYY group (control 59 days vs SYY 67 days, *P* = .041), by 9 days in the MS group (control 59 days vs MS 68 days, *P* = .041), and by 16 days in the MS-SYY group (control 59 days vs SYY-MS 75 days, *P* = .016; [Figure 1E](#fig1-1534735415622011){ref-type="fig"}).

![SYY combined with MS suppressed growth and lung metastases of transplanted liver cancer in a mouse model. (A) Subcutaneous Hepa1-6 hepatomas were dissected 42 days after inoculation. Hepatomas were analyzed from each of the 4 groups (control, SYY, MS, and SYY-MS; n = 6 in each group). The tumor weights (mean ± SD) were quantified and plotted in (B). (C) Four representative foci from lung metastases from Hepa1-6-GFP-inoculated animals (n = 6 in each group) 42 days after injection through the tail vein. The relative lung metastases sizes (mean ± SD) are quantified and plotted in (D). (E) Log-rank survival analysis of the 4 groups. For all panels, \**P* \< .05 and \*\**P* \<.01.\
Abbreviations: SYY, *Songyou Yin*; MS, moderate swimming; GFP, green fluorescent protein.](10.1177_1534735415622011-fig1){#fig1-1534735415622011}

SYY Combined With MS Markedly Increased CD4/CD8 Ratio in Peripheral Blood {#section13-1534735415622011}
-------------------------------------------------------------------------

Compared with the control group, CD4 + T lymphocyte proportion in PBMC was increased in the SYY group (*P* \< .05) and MS group (*P* \< .05) and dramatically in the SYY-MS group (*P* \< .01). There was no significant difference in CD8 + T lymphocyte proportions in PBMC among the 4 groups ([Table 1](#table1-1534735415622011){ref-type="table"}, [Figures 2A](#fig2-1534735415622011){ref-type="fig"} and [2B](#fig2-1534735415622011){ref-type="fig"}). Compared with the control group, the CD4 to CD8 ratio was increased in the SYY group (*P* \< .05) and MS group (*P* \< .05) and dramatically in the MS-SYY group (*P* \< .01, [Table 1](#table1-1534735415622011){ref-type="table"}, [Figure 2C](#fig2-1534735415622011){ref-type="fig"}).

###### 

Peripheral Blood CD4+ and CD8+ T Cell Proportion and CD4 to CD8 Ratio in the 4 Groups.^[a](#table-fn2-1534735415622011){ref-type="table-fn"}^

![](10.1177_1534735415622011-table1)

                    Control        SYY                                                                  MS                                                                   SYY-MS
  ----------------- -------------- -------------------------------------------------------------------- -------------------------------------------------------------------- ----------------------------------------------------------------------
  CD4+ T cell (%)   15.38 ± 2.24   22.26 ± 2.51[\*](#table-fn2-1534735415622011){ref-type="table-fn"}   21.96 ± 3.01[\*](#table-fn2-1534735415622011){ref-type="table-fn"}   26.88 ± 4.32[\*\*](#table-fn2-1534735415622011){ref-type="table-fn"}
  CD8+ T cell (%)   11.68 ± 2.76   12.15 ± 2.14[\*](#table-fn2-1534735415622011){ref-type="table-fn"}   12.43 ± 2.27[\*](#table-fn2-1534735415622011){ref-type="table-fn"}   13.02 ± 2.68[\*\*](#table-fn2-1534735415622011){ref-type="table-fn"}
  CD4/CD8 ratio     1.32 ± 0.36    1.83 ± 0.49[\*](#table-fn2-1534735415622011){ref-type="table-fn"}    1.77 ± 0.34[\*](#table-fn2-1534735415622011){ref-type="table-fn"}    2.07 ± 0.25[\*\*](#table-fn2-1534735415622011){ref-type="table-fn"}

Abbreviations: SYY, *Songyou Yin*; MS, moderate swimming.

Data are presented as the mean ± SD. \**P* \< .05, \*\**P* \< .01 (indicates a significant difference with respect to the control group).

![SYY combined with MS increased the CD4 to CD8 ratio in peripheral blood. (A) Flow cytometric analysis of CD4+ and CD8+ T cell proportions in PBMC from tumor-burdened C57 mice treated with SYY, MS, and SYY-MS. The proportion of CD4+ and CD8+ T cells in PBMC were quantified and plotted in (B). (C) CD4+/CD8+ T cells ratio of PBMC from C57BL/6 mice of the 4 groups. For all panels, n = 6 in each group. For all panels, \**P* \< .05 and \*\**P* \< .01.\
Abbreviations: SYY, *Songyou Yin*; MS, moderate swimming; PBMC, peripheral blood monocyte.](10.1177_1534735415622011-fig2){#fig2-1534735415622011}

SYY Combined With MS Markedly Reduced Serum TGF-β1 Levels {#section14-1534735415622011}
---------------------------------------------------------

Serum TGF-β1 levels were detected in mice of 4 groups. Compared with the control group, TGF-β1 was significantly decreased ([Figure 3](#fig3-1534735415622011){ref-type="fig"}) in the SYY group (control 50.16 ± 16.35 pg/mL vs SYY 39.17 ± 13.26 pg/mL, *P* \< .05), MS group (control 50.16 ± 16.35 pg/mL vs MS 36.53 ± 12. 46 pg/mL, *P* \< .05), and SYY-MS group (control 50.16 ± 16.35 pg/mL vs SYY-MS 31.64 ± 10.19 pg/mL, *P* \< .01).

![TGF-β1 levels in the serum of tumor-burdened mice exposed to SYY, MS, and SYY-MS; n = 6 in each group. \**P* \< .05 and \*\**P* \< .01.\
Abbreviations: SYY, *Songyou Yin*; MS, moderate swimming; TGF, transforming growth factor.](10.1177_1534735415622011-fig3){#fig3-1534735415622011}

SYY Combined With MS Markedly Decreased CD4+ CD25+ Foxp3+ Treg Proportion in Peripheral Blood, Spleen, and Tumor Tissue {#section15-1534735415622011}
-----------------------------------------------------------------------------------------------------------------------

Tregs comprise a subgroup of T lymphocytes with immune suppressive properties. Compared with controls, the proportion of CD4+ CD25+ Foxp3+ Tregs in PBMC, spleen lymphocytes, and TIL were significantly decreased in the SYY (*P* \< .05) and MS groups (*P* \< .05) and dramatically in the SYY-MS group (*P* \< .01, [Table 2](#table2-1534735415622011){ref-type="table"} and [Figures 4A](#fig4-1534735415622011){ref-type="fig"}[](#fig4-1534735415622011){ref-type="fig"}[](#fig4-1534735415622011){ref-type="fig"}-[4D](#fig4-1534735415622011){ref-type="fig"}).

###### 

The Proportion of CD4+ CD25+ Foxp3+ Treg Cells in Peripheral Blood, Spleen, and Tumor Tissues.^[a](#table-fn4-1534735415622011){ref-type="table-fn"}^

![](10.1177_1534735415622011-table2)

  Treg Cells Proportion     Control       SYY                                                                 MS                                                                  SYY-MS
  ------------------------- ------------- ------------------------------------------------------------------- ------------------------------------------------------------------- ---------------------------------------------------------------------
  In peripheral blood (%)   3.27 ± 0.35   2.63 ± 0.32[\*](#table-fn4-1534735415622011){ref-type="table-fn"}   2.58 ± 0.28[\*](#table-fn4-1534735415622011){ref-type="table-fn"}   2.24 ± 0.37[\*\*](#table-fn4-1534735415622011){ref-type="table-fn"}
  In spleen (%)             4.38 ± 0.52   3.77 ± 0.33[\*](#table-fn4-1534735415622011){ref-type="table-fn"}   3.69 ± 0.41[\*](#table-fn4-1534735415622011){ref-type="table-fn"}   3.46 ± 0.29[\*\*](#table-fn4-1534735415622011){ref-type="table-fn"}
  In tumor tissue (%)       2.75 ± 0.26   2.12 ± 0.28[\*](#table-fn4-1534735415622011){ref-type="table-fn"}   2.16 ± 0.35[\*](#table-fn4-1534735415622011){ref-type="table-fn"}   1.66 ± 0.21[\*\*](#table-fn4-1534735415622011){ref-type="table-fn"}

Abbreviations: SYY, *Songyou Yin*; MS, moderate swimming.

Data are presented as the mean ± SD. \**P* \< .05, \*\**P* \< .01 (indicates a significant difference with respect to the control group).

![SYY combined with MS reduced CD4+CD25+Foxp3+ Treg cell proportions in PBMC, spleen, and TIL from tumor-burdened mice. A. Flow cytometric selection and analysis for CD4+ CD25+ Foxp3+ Treg cell. B. Treg cell proportion in PBMC from C57BL/6 mice. C. Treg cell proportion in spleen lymphocytes. D. Treg cell proportion in TIL. For all panels, n = 6 in each group. For all panels, \**P* \< .05 and \*\**P* \< .01.\
Abbreviations: SYY, *Songyou Yin*; MS, moderate swimming; PBMC, peripheral blood monocyte; TIL, tumor-infiltrating lymphocytes.](10.1177_1534735415622011-fig4){#fig4-1534735415622011}

Discussion {#section16-1534735415622011}
==========

With a history of more than 2000 years, traditional Chinese Medicine (TCM) has formed a unique theoretical system and had a practical clinical effect. Chinese herbal medicine is the most common modality of TCM.^[@bibr15-1534735415622011],[@bibr26-1534735415622011]^ TCM was used against cancer for centuries, and one of its primary treatment principles is *Fuzheng*---namely, enhancing immunocompetence.^[@bibr27-1534735415622011]^ As is well known, physical exercise has been observed to reduce the morbidity and mortality associated with malignant tumors, mainly by enhancement of immunity.^[@bibr9-1534735415622011],[@bibr10-1534735415622011]^

An immunosuppressive status facilitates growth and metastasis of malignant tumors, and immunotherapy for cancer has been specifically emphasized recently.^[@bibr6-1534735415622011]^ This study showed that the Chinese herbal formula SYY combined with moderate swimming training markedly suppressed growth and experimental lung metastasis of liver cancer and prolonged survival in a mouse model by enhancing immune function. SYY plus MS markedly raised the CD4 to CD8 ratio and reduced the serum TGF-β1 levels and proportion of Tregs in peripheral blood, spleen, and tumor tissue in tumor-burdened mice. The effects of the combined intervention were significantly superior to SYY or MS alone.

There are many studies of drug combinations (including combinations of Western medicines or Western medicine and herbal medicine) in the therapy of cancers, and most of them exhibit enhanced or synergistic efficacy and reduced toxicity.^[@bibr28-1534735415622011][@bibr29-1534735415622011][@bibr30-1534735415622011][@bibr31-1534735415622011]-[@bibr32-1534735415622011]^ To our knowledge, there is no related report on the combined application of physical exercise and herb medicine in cancers. But there are studies on combined exercise and diet. A previous study showed that both short-term moderate exercise training and consumption of the soluble oat β-glucan can decrease the metastatic spread of injected B16 melanoma cells by increasing macrophage cytotoxicity; the 2 therapies, however, had no additive effects.^[@bibr11-1534735415622011]^ It has also been shown that swimming training may attenuate liver carcinogenesis under an adequate dietary regimen with lowered fat intake.^[@bibr13-1534735415622011]^

CD4+ T cells play a central role in initiating and maintaining anticancer immune responses.^[@bibr33-1534735415622011]^ Impairment of CD4+ cytotoxic T cells predicts poor survival and high recurrence rates in patients with HCC.^[@bibr34-1534735415622011]^ Clinically, the CD4 to CD8 ratio is a key criterion to evaluate the immune status, and a reverse CD4 to CD8 ratio usually indicates tumor progression and poor prognosis.^[@bibr29-1534735415622011],[@bibr31-1534735415622011]^ The cytokine TGF-β plays a role in immunosuppression, and tumors that produce high levels of TGF-β may be shielded from immune surveillance.^[@bibr35-1534735415622011]^ Treg cells, a subgroup of T cells with immunosuppressive property have been confirmed to play an important role in HCC.^[@bibr22-1534735415622011],[@bibr32-1534735415622011]^ Liver cancer cells can recruit Tregs or induce differentiation of CD4+ T cells to Tregs by secreting TGF-β1, as a result creating an immunosuppressive microenvironment that promotes tumor growth and metastasis.^[@bibr22-1534735415622011],[@bibr36-1534735415622011]^

The effect of SYY in the treatment of liver cancer has been studied for nearly 10 years. This series of studies showed that SYY can inhibit growth and metastasis of liver cancer by downregulating vascular endothelial growth factor (VEGF) and matrix metalloproteinase 2 expression,^[@bibr17-1534735415622011]^ enhancing the antitumor capacity of interferon-α,^[@bibr18-1534735415622011]^ reversing epithelial to mesenchymal transition (EMT) induced by chemotherapy,^[@bibr19-1534735415622011]^ reducing the proportion of cancer stem cells in liver cancer tissue cells,^[@bibr20-1534735415622011]^ and inhibiting the secretion of cytokines: hepatocyte growth factor, interleukin 6, TGF-β, and VEGF by hepatic stellate cells.^[@bibr21-1534735415622011]^ These experimental results indicate that the tumor-suppressing effect of SYY is complex. The present study revealed that enhancing immunity is the novel mechanism underlying SYY suppression of liver cancer. In this study, SYY suppressed experimental growth and lung metastasis of liver cancer in mice by raising CD4+ T lymphocytes in peripheral blood and reducing serum TGF-β1 level and CD4+ CD25+ Foxp3+ Treg percentage in blood, spleen, and tumor tissue. TGF-β potently suppresses CD4+ T cell differentiation and effector functions of cytotoxic CD8+ T cells^[@bibr37-1534735415622011]^ and promotes proliferation and activation of Treg cells.^[@bibr22-1534735415622011]^ Previous studies showed that SYY inhibits the secretion of TGF-β by hepatic stellate cells^[@bibr21-1534735415622011]^; thus, reduction of serum TGF-β1 may be an initiating factor causing the reduction of Treg proportions and rise of CD4 to CD8 ratio in the study.

The World Health Organization recommends regular physical activity to reduce the risk of cancers,^[@bibr38-1534735415622011]^ and physical activity has even been recommended as a standard cancer treatment.^[@bibr10-1534735415622011]^ The mechanism underlying the ability of physical exercise to suppress tumor progression is quite complicated. Postulated mechanisms underlying the potential effects of exercise on cancer progression include modulation of metabolic (eg, glucose-insulin homeostasis) and sex-steroid (eg, estrogens) hormone levels, improvements in immune surveillance, and reduced systemic inflammation and oxidative damage.^[@bibr39-1534735415622011]^ Among these, exercise-induced immunomodulation has received a great deal of attention in the exercise oncology field.^[@bibr40-1534735415622011][@bibr41-1534735415622011][@bibr42-1534735415622011]-[@bibr43-1534735415622011]^ Furthermore, physical activity can have different influences on carcinogenesis, depending on intensity, duration, and frequency of activity.^[@bibr44-1534735415622011]^ Moderate regular exercise exhibits cancer-preventive potential, whereas exhaustive exercise may increase the risk of development of some cancers.^[@bibr45-1534735415622011]^ Wang et al^[@bibr41-1534735415622011]^ showed that moderate-intensity exercise lowered the risk of cancer and infectious illness through enhancing proinflammatory responses, whereas high-intensity exercise might increase the risk of common infections because of an upregulation of CD4+CD25+ Treg cells and anti-inflammatory responses. Demarzo et al^[@bibr46-1534735415622011]^ reported that exhaustive physical exercise increased the susceptibility of rats to colon cancer via increased free radical DNA oxidative damage and depressed immune function. Murphy et al,^[@bibr11-1534735415622011]^ however, reported that moderate exercise can decrease lung metastases of B16 melanoma via increased macrophage antitumor cytotoxicity. Consistent with previous studies, our results showed that MS exercise suppressed growth and lung metastasis of liver cancer in mice via enhancement of immunity represented by a rise in CD4 to CD8 ratio in peripheral blood and reduction of serum TGF-β1 and CD4+ CD25+ Foxp3+ Treg proportion in PBMC, spleen lymphocytes, and TIL.

Conclusion {#section17-1534735415622011}
==========

The combined intervention of SYY and MS exerted enhanced effects on suppressing growth and lung metastasis of liver cancer via dramatic enhancement of immunocompetence, and the effect is superior to SYY or MS alone. Although the herbal compound SYY and swimming exercise are 2 quite different types of intervention, they had similar effects on strengthening immunity and suppressing liver cancer progression. Whether this model would be beneficial for patients suffering from malignant tumors would need further clinical study in the future.
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